Blending Science & Impact in Drug Development: Felix Boakye-Agyeman, Vice President of the QSS Division at Certara Blog Post
You may also like AllVideo Behind the Science: Meet Project Manager Chantal MorinBehind the Science: Meet Project Manager Chantal MorinVideoBehind the Science: Meet Project Manager Chantal Morin Bridging Strategy &...
Behind the Science: Meet Project Manager Chantal Morin Blog Post
You may also like AllVideo Blending Science & Impact in Drug Development: Felix Boakye-Agyeman, Vice President of the QSS Division at CertaraBlending Science & Impact in Drug Development: Felix Boakye-Agyeman,...
Exploring Common CDISC ADaM Conformance Findings Blog Post
Trevor Mankus Product Manager 2025 年 3 月 27 日 Intro to CDISC ADaM Conformance ADaM data are required by the FDA and PMDA and accepted by China’s NMPA. Agencies often begin reviews...
Bridging Strategy & Execution: Sophia Fong’s Approach to Drug Development Blog Post
You may also like AllVideo Blending Science & Impact in Drug Development: Felix Boakye-Agyeman, Vice President of the QSS Division at CertaraBlending Science & Impact in Drug Development: Felix Boakye-Agyeman,...
Behind the Science: Meet Sr. Director Craig Comisar Blog Post
You may also like AllVideo Blending Science & Impact in Drug Development: Felix Boakye-Agyeman, Vice President of the QSS Division at CertaraBlending Science & Impact in Drug Development: Felix Boakye-Agyeman,...
Behind the Science: Meet Project Manager Holly Dierkers Blog Post
You may also like AllVideo Blending Science & Impact in Drug Development: Felix Boakye-Agyeman, Vice President of the QSS Division at CertaraBlending Science & Impact in Drug Development: Felix Boakye-Agyeman,...
Introducing the new Certara.com: Transforming drug development for good, together. Blog Post
Sheila Rocchio 2025 年 3 月 26 日 We’re thrilled to introduce the launch of our revamped website and refreshed brand—welcome to the new Certara.com! This is more than a simple visual update;...
QSP Modeling Optimizes FIH Dose Selection for Multiple Myeloma Therapy Blog Post
Multiple myeloma, the second most common blood cancer, affects an estimated 160,000 individuals annually worldwide (Ludwig et al. 2020). Despite advancements in therapies like monoclonal antibodies and T-cell engages (TCEs),...
